These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17172780)

  • 1. 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users.
    McCambridge J; Winstock A; Hunt N; Mitcheson L
    Eur Addict Res; 2007; 13(1):57-64. PubMed ID: 17172780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year trends in patterns of drug use among people who use stimulants in dance contexts in the United Kingdom.
    McCambridge J; Mitcheson L; Winstock A; Hunt N
    Addiction; 2005 Aug; 100(8):1140-9. PubMed ID: 16042644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample.
    Winstock AR; Kaar S; Borschmann R
    J Psychopharmacol; 2014 Jan; 28(1):49-54. PubMed ID: 24284475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases.
    Licht CL; Christoffersen M; Okholm M; Damgaard L; Fink-Jensen A; Knudsen GM; Erritzoe D
    Hum Psychopharmacol; 2012 Jul; 27(4):352-63. PubMed ID: 22696164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methoxetamine: An early report on the motivations for use, effect profile and prevalence of use in a UK clubbing sample.
    Winstock AR; Lawn W; Deluca P; Borschmann R
    Drug Alcohol Rev; 2016 Mar; 35(2):212-7. PubMed ID: 25867295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths.
    Wu LT; Schlenger WE; Galvin DM
    Drug Alcohol Depend; 2006 Sep; 84(1):102-13. PubMed ID: 16483730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hallucinogen use among young adults ages 19-30 in the United States: Changes from 2018 to 2021.
    Keyes KM; Patrick ME
    Addiction; 2023 Dec; 118(12):2449-2454. PubMed ID: 37287110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing use of "Ecstasy" (MDMA) and other hallucinogens on a college campus.
    Cuomo MJ; Dyment PG; Gammino VM
    J Am Coll Health; 1994 May; 42(6):271-4. PubMed ID: 7913938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
    De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G
    J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adolescent and adult time trends in US hallucinogen use, 2002-19: any use, and use of ecstasy, LSD and PCP.
    Livne O; Shmulewitz D; Walsh C; Hasin DS
    Addiction; 2022 Dec; 117(12):3099-3109. PubMed ID: 35978453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent trends in the use of "club drugs": an Australian review.
    Degenhardt L; Copeland J; Dillon P
    Subst Use Misuse; 2005; 40(9-10):1241-56. PubMed ID: 16048815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of psychedelics in the Czech Republic: results of recent population surveys.
    Chomynová P; Kočárová R; Kňažek F; Plevková M; Bláhová B; Valeš K; Mravčík V
    Cent Eur J Public Health; 2022 Sep; 30(3):144-153. PubMed ID: 36239361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of an international nightlife resort in the proliferation of recreational drugs.
    Bellis MA; Hughes K; Bennett A; Thomson R
    Addiction; 2003 Dec; 98(12):1713-21. PubMed ID: 14651503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in drug use among electronic dance music party attendees in New York City, 2016-2019.
    Palamar JJ; Keyes KM
    Drug Alcohol Depend; 2020 Apr; 209():107889. PubMed ID: 32050110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Club drug use among youths in treatment for substance abuse.
    Hopfer C; Mendelson B; Van Leeuwen JM; Kelly S; Hooks S
    Am J Addict; 2006; 15(1):94-9. PubMed ID: 16449098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [COMPARISON OF PSYCHOPHARMACA LSD-25, BOL-148 AND PSILOCYBIN IN CLINICAL PRACTICE].
    KANDIC B; DORDEVIC D
    Vojnosanit Pregl; 1963 May; 20():275-9. PubMed ID: 14067329
    [No Abstract]   [Full Text] [Related]  

  • 18. Ecstasy and drug consumption patterns: a Canadian rave population study.
    Gross SR; Barrett SP; Shestowsky JS; Pihl RO
    Can J Psychiatry; 2002 Aug; 47(6):546-51. PubMed ID: 12211882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):46-56. PubMed ID: 34983249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
    Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.